文献速递神经MR

多发性硬化中钆基对比剂的使用:ESMRMB-GREC与ESNR多发性硬化工作组综述

Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group.
PubMed 文献 · Eur Radiol · 2023-09-02

该综述由ESMRMB-GREC与ESNR多发性硬化工作组撰写,阐述钆基对比剂在多发性硬化中的作用机制、临床适应证、诊断/预后/监测价值及儿童、孕妇和哺乳期等特殊人群的使用,并讨论在符合各监管机构安全规定前提下检测强化病灶的最高敏感度成像策略及替代方法。

要点

  • EMA与FDA均要求钆基对比剂仅用于额外信息为临床所必需的场景。
  • 疑似多发性硬化诊断评估中一般推荐使用钆基对比剂,常规监测一般不需要。
  • 常规监测中疾病活动可依据T2加权图像上新发或增大病灶来识别。

核心结论

  • 尽管钆基对比剂在疑似多发性硬化的诊断评估中极具诊断和预后价值,但其在常规监测中并非必需且必须减少使用,因为疾病活动可通过T2加权图像上新发或增大病灶的识别来判定。

研究设计与样本

  • 本文为ESMRMB-GREC与ESNR多发性硬化工作组撰写的综述,未报告系统检索范围与纳入文献数量。

关键影像表现/征象

  • T1加权序列上的强化病灶与(亚)急性炎症相关,新发或增大的T2病灶反映既往急性炎症性脱髓鞘事件的永久痕迹。
  • 这两类MRI特征提供冗余信息,至少在疾病的常规监测中如此。

诊断标准与关键数值

  • 临床实践中多发性硬化病灶的检测主要基于T2加权和增强T1加权序列。

临床应用与阅片要点

  • EMA和FDA指出,医学中钆基对比剂的使用应限制在需要对比剂提供额外信息的临床场景。
  • 疑似多发性硬化的诊断评估中一般推荐使用钆基对比剂,临床实践中的常规监测一般不需要。
  • 用于检测急性局灶性炎症性多发性硬化病灶的替代MRI方法尚未准备好在临床实践中使用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Magnetic resonance imaging (MRI) is the most sensitive technique for detecting inflammatory demyelinating lesions in multiple sclerosis (MS) and plays a crucial role in diagnosis and monitoring treatment effectiveness, and for predicting the disease course. In clinical practice, detection of MS lesions is mainly based on T2-weighted and contrast-enhanced T1-weighted sequences. Contrast-enhancing lesions (CEL) on T1-weighted sequences are related to (sub)acute inflammation, while new or enlarging T2 lesions reflect the permanent footprint from a previous acute inflammatory demyelinating event. These two types of MRI features provide redundant information, at least in regular monitoring of the disease. Due to the concern of gadolinium deposition after repetitive injections of gadolinium-based contrast agents (GBCAs), scientific organizations and regulatory agencies in Europe and North America have proposed that these contrast agents should be administered only if clinically necessary. In this article, we provide data on the mode of action of GBCAs in MS, the indications of the use of these agents in clinical practice, their value in MS for diagnostic, prognostic, and monitoring purposes, and their use in specific populations (children, pregnant women, and breast-feeders). We discuss imaging strategies that achieve the highest sensitivity for detecting CELs in compliance with the safety regulations established by different regulatory agencies. Finally, we will briefly discuss some alternatives to the use of GBCA for detecting blood-brain barrier disruption in MS lesions. CLINICAL RELEVANCE STATEMENT: Although use of GBCA at diagnostic workup of suspected MS is highly valuable for diagnostic and prognostic purposes, their use in routine monitoring is not mandatory and must be reduced, as detection of disease activity can be based on the identification of new or enlarging lesions on T2-weighted images. KEY POINTS: • Both the EMA and the FDA state that the use of GBCA in medicine should be restricted to clinical scenarios in which the additional information offered by the contrast agent is required. • The use of GBCA is generally recommended in the diagnostic workup in subjects with suspected MS and is generally not necessary for routine monitoring in clinical practice. • Alternative MRI-based approaches for detecting acute focal inflammatory MS lesions are not yet ready to be used in clinical practice.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Rovira À, Doniselli FM, Auger C, et al. Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group. Eur Radiol. 2023. PMID: 37658891. doi:10.1007/s00330-023-10151-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。